Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma

Abstract

Osteosarcoma is a rare disease characterized by the production of tumoral osteoid or immature bone after the proliferation of malignant osteoblasts. [1] Treatment of osteosarcoma is primarily based on neoadjuvant and adjuvant chemotherapy (CT) and surgical resection. With developments over the years, the combined use of surgical treatment and CT has significantly increased the cure and survival rates of patients. [2] Although multimodal therapy has greatly improved patients' oncological outcomes, the prognosis of metastatic or recurrent osteosarcoma is still unsatisfactory.Although many prognostic factors affecting the course of the disease have been described in the literature, controversial results have been reported.Objectives: This study aims to examine the clinical results of patients who underwent medical and surgical treatment for osteosarcoma, to determine the overall survival (OS) and disease-free survival (DFS) rates, and to examine the effects of prognostic factors on these rates. Patients and methods: Between January 2005 and January 2020, a total of 64 patients (38 males, 26 females; mean age: 20.9±11.5 years; range, 6 to 70 years) who received medical and surgical treatment for osteosarcoma were retrospectively analyzed. Demographic characteristics, follow-up period, tumor location and size, tumor stage and necrosis rate, metastatic disease, surgical treatments, postoperative complications, local recurrence, and metastasis were recorded. The relationship of these factors with the survival was examined. Results: The median follow-up was 51.6 (range, 3 to 156) months. The most common tumor localization was in the distal femur with 42 (65.6%) patients and the most common histopathological subtypes were conventional osteosarcoma in 50 (78.1%) patients. The OS rates were 91.6% at one year, 65.9% at five years, and 51.6% at 10 years. With the exception of two patients who died during neoadjuvant chemotherapy, all patients underwent surgical treatment. The addition of chemotherapy + radiotherapy in the treatment did not provide any benefits in terms of survival and recurrence compared to the group that was not added, and the five-year OS rate was 79.3% compared to 20.7%, respectively. The overall 10-year survival rates were 83.9% and 37.2% in the group with a good response (≥90%) and poor response (<90%) to treatment (p=0.012). The mean survival time of three patients who presented with pathological fractures was shorter than the others (p>0.05). Surgical margin was ≤2 mm in 27 (42.2%) patients, >2 mm in 30 (46.9%) patients, and surgical margin was positive in five (7.8%) patients. The mean OS in the group with a surgical margin closure of >2 mm was 10.8±1.9 years and was longer than the other groups (p=0.047). Conclusion: Metastasis at the time of diagnosis, <90% tumor necrosis, a tumor size of ≥10 cm, and metastasis development were significantly associated with poor survival and were found to be independent prognostic factors. The OS rate in the patient group with Stage III-IV response after neoadjuvant...

Osteosarcoma of the Proximal Fibula: A Case Report and Review of the Literature

“…The metastatic spread of the disease is primarily to the lungs (80% to 90%) via the venous route [ 3 ]. With the medical oncology department's evaluation, chemotherapy is administered to the patient with a high percentage of necrosis to prevent local recurrence after surgical treatment [ 10 , 11 ]. Therefore, follow-up and treatment of a patient after surgery must be managed with a multidisciplinary approach.…”

Identification of New Potential Prognostic and Predictive Markers in High-Grade Osteosarcoma Using Whole Exome Sequencing

“…Prabowo et al proposed a scoring system predicting response to neoadjuvant chemotherapy based on integrating the histology with clinical data, e.g., gender, age and increased tumor size after neoadjuvant chemotherapy [ 6 ]. Other authors found that metastasis at diagnosis, tumor size larger than 10 cm and metastasis development are factors that are significantly associated with poor survival, and function as independent prognostic factors [ 7 ].…”